A rapid assay was developed to screen for herpes simplex virus (HSV) isolates that are resistant to acyclovir and other antiviral agents. The assay is a modified plaque reduction assay (PRA) in which the number of plaques seen in the absence of acyclovir was compared with that seen in the presence of a single cutoff concentration of acyclovir (2 mg/mL). This assay utilizes a cell line that expresses b-galactosidase only after infection with HSV. Since histochemically stained plaques are easily visualized, small plaques can be easily enumerated. This allows the assay to be performed on dilutions of untitered specimens in the small wells of a 24-well plate and allows the results to be read only 2 days after inoculation of the virus. The assay performed well compared with a standard PRA and should be a valuable tool in identifying drug-resistant HSV in a timely manner.
Herpes simplex virus (HSV) is a highly prevalent human
Recently, we described a modified PRA based on the use of a genetically engineered Vero cell line that expresses pathogen that is especially problematic for immunocompromised hosts [1] . A number of antiherpesvirus agents have beb-galactosidase only after infection with HSV [11] . In this report, we describe our results with a CV1-derived cell line come available, but acyclovir (Glaxo-Wellcome, Research Triangle Park, NC) remains the drug of choice for the treatment (CV19 cells) that expresses higher levels of b-galactosidase after HSV infection. We tested the performance of the CV19 of most HSV infections [2] . Resistance to acyclovir can appear during treatment, but because of the self-limited nature of HSV cells in a rapid screening assay, the modified PRA (ELVIRA; Diagnostic Hybrids, Athens, OH), the format of which allows infections in normal hosts, acyclovir resistance is not a clinically significant problem in most cases [3] . However, immunoan isolate to be scored as sensitive or resistant to acyclovir within 48 h of the time the culture is positive [12] . suppressed patients rely on specific antiviral therapy for clinical improvement, and resistance can emerge, especially when these patients have been taking antiviral agents for long periods Material and Methods [3] [4] [5] . In these cases, an alteration in antiviral therapy is necessary for successful outcome; therefore, the identification of CV19 cells. CV1 cells were obtained from the American Type acyclovir-resistant isolates has become increasingly important Culture Collection (ATCC, Rockville, MD). Clone CV19 was iso- [3, 6] . lated in an identical manner as the previously described VeroIC-A number of assays are available to identify HSV isolates P6LacZ cells [11] . CV19 cells were maintained in Dulbecco's that are resistant to antivirals such as acyclovir, but the plaque MEM supplemented with 10% fetal calf serum and hygromycin reduction assay (PRA) is generally considered to be the refer-B (100 mg/mL; Boehringer Mannheim, Indianapolis). Viral sensitivity testing. A standard PRA was done by using ence standard [7] [8] [9] [10] . A major advantage of the PRA is that CV1 cells as previously described [11] . An IC 50 of §2 mg/mL was it utilizes the exquisite sensitivity of the viral plaque, which is used as the cutoff for scoring an isolate as resistant to acyclovir.
the consequence of a single virus particle initiating infection containing an antiviral was added to each well. Therefore, for each dilution of virus, there was 1 well with no drug, 1 well with acyclovir (Sigma, St. Louis) at 2 mg/mL, and 1 well with foscarnet (Sigma) at 300 mg/mL. Pooled human immune globulin (Amour often contained an excessive viral inoculum, and the plaques were For these isolates, untitered, first-passage stocks, stored at 080ЊC, were thawed. After low-speed centrifugation, the supernatant, ditoo numerous to count. The row (dilution) that produced 10-100 plaques in the well without antiviral was used to score sensitivity. luted as described above, was used as the virus inoculum. Several of the clinical isolates came from patients with AIDS who had been If the number of plaques in the acyclovir well was ú50% of the number seen in the absence of acyclovir, the virus was considered treated with acyclovir for long periods. Typing was not performed. Another 7 well-characterized isolates were obtained from D. resistant. We included a well with a high concentration of foscarnet (300 mg/mL) to provide a control in which viral replication was McCleron (Burroughs Wellcome, Research Triangle Park, NC). completely inhibited. The modified PRA was performed and scored blind to the results of the standard PRA.
Results
Viruses. HSV-1 (KOS strain) was obtained from M. Challberg (NIH, Bethesda, MD). A thymidine kinase (tk) deletion mutant
To evaluate the performance of the CV19 cells, we per- in the presence of foscarnet (data not shown). The IC 50 for acyclovir for strain KOS (õ0.1 mg/mL) and dlsptk (ú20 methods to evaluate the effect of antivirals on virus growth require cell culture methodology; (3) genetic modification of mg/mL) was the same when the PRA was performed using CV1 and CV19 cells (data not shown).
cells can improve and simplify cell culture-based methods; (4) plaque-based methods have certain advantages in antiviral Forty-six clinical isolates that had previously undergone standard PRA to determine susceptibility to acyclovir were susceptibility testing; and (5) a rapid screening test that gives sensitivity and resistance determinations can provide valuable evaluated by modified PRA. Twenty-three isolates (50%) were resistant to acyclovir (IC 50 §2) in the standard PRA and the information for the clinician and could dramatically reduce the number of isolates submitted to a more time-consuming IC 50 other 23 were sensitive. Figure 1B shows a typical example of how the test appears under low-power (140) light microscopy.
assay. The PRA has been the reference standard in antiviral suscepIn the absence of drug or with drug-resistant isolates, plaques are seen as clusters of blue cells. In the presence of inhibitory tibility testing of HSV, and it is the only method for which a study has shown a clinical correlation between treatment outconcentrations of the drug, single blue (dark) cells are seen (Figure 1Bb, arrowhead) .
come and in vitro assay results [13] . The plaque assay has been a critical tool in the field of HSV biology and has formed the Among the 46 isolates tested, 44 showed agreement between the results of standard and modified PRA. One isolate did not cornerstone of studies of HSV replication and genetics, because it has allowed the quantitation of viral replication and the isolaform discrete plaques in the modified PRA, and therefore could not be scored. One clinical isolate with an IC 50 for acyclovir tion of clonal strains and mutants [14] . The PRA is, therefore, highly grounded in HSV biology and has many advantages in of 3.5 mg/mL by standard PRA was scored as sensitive by modified PRA. The test identified 96% of the clinical specievaluating the behavior of HSV in the presence of an antiviral. Alternative, less cumbersome, cell culture-based methods mens correctly as sensitive or resistant. The prevalence of resistance to acyclovir (50%) of the isolates we tested is comparable have been developed, but they have not received wide acceptance [7] . to the overall prevalence of resistance of isolates submitted for drug sensitivity testing to our Clinical Virology Laboratory.
The modified PRA described here solves many of the problems inherent to the PRA while preserving the merits of a Excluding the isolate that could not be scored by modified PRA, and using standard PRA as reference standard, the modiplaque-based assay. It provides results that are directly comparable to those of standard PRA and it has excellent sensitivity fied PRA had a sensitivity of 95.5%, a specificity of 100%, a positive predictive value of 100%, and a negative predictive and specificity. It does not provide an IC 50 , but it provides a qualitative determination that an isolate is either resistant or value of 95.8%.
sensitive. This determination may be sufficient for the clinician to make the appropriate therapeutic decision. In addition, the Discussion modified PRA is easy to perform, and the materials and equipment it requires are readily available to any clinical virology Although, in most cases, physicians do not treat serious bacterial infections without ordering antibiotic susceptibility laboratory. Although, for the purposes of the present study, the assay was designed for acyclovir susceptibility testing, susceptesting on the causative organism, this is done routinely for HSV infections. A number of factors contribute to this: First, tibility to virtually any anti-HSV drug could be tested. The modified PRA could also be used to analyze isolates not all physicians have access to a clinical virology laboratory. Second, results of antiviral susceptibility testing are not usually taken directly from patients. There are clinical circumstances in which a patient has had recurrent or persistent HSV infecavailable on a timely basis. Third, standards have not yet been established for antiviral susceptibility testing. Finally, the pertions-the diagnosis has already been confirmed but it is important to determine whether the ongoing infection is due to a ception has been that there is not much need for rapid antiviral susceptibility testing. drug-resistant virus. This would be an ideal situation in which to screen the specimen directly for resistance without amplifiThis work is a part of our overall goal to reduce the effort and time required for the laboratory to perform antiviral suscepcation of the isolate. We have taken swab specimens from patient lesions and tested these specimens in the modified PRA. tibility testing and, concomitantly, to lower the threshold for the clinician to order it. We envision a future in which, as
We found that Ç70% of such specimens contained sufficient amounts of virus for the modified PRA (data not shown). is the case with antibacterial susceptibility testing, antiviral susceptibility testing is done routinely in clinical situations in Finally, the modified PRA has the ability to identify a subpopulation of resistant viruses in a population that appears which it is warranted. To accomplish this goal, many clinical and technical problems need to be solved.
overall to be sensitive. For a number of isolates, we observed a reduction of ú50% in the number of plaques in the acyclovirIn the present study, we addressed the technical issues. We approached the design of antiviral susceptibility testing with the containing well compared with the no-drug well, and thus the isolate was scored as sensitive. However, in these cases, a following notions: (1) Although genotypic tests are valuable, phenotypic tests will always be necessary; (2) as obligate intrasignificant number of plaques were present in the acyclovir well, indicating the presence of a resistant subpopulation. The cellular pathogens, viruses replicate only in cells, and therefore JID 1998;177 (January) with the plaque reduction assay for measuring the sensitivity of herpes simplex virus and varicella-zoster virus to penciclovir and acyclovir. J Virol Methods 1996;56:3-11.
